In partnership with the several big-name cancer centers, one company has commenced clinical trials. Find out how this cancer vaccine would work.
Leukemia and Lymphoma
The high cost of specialty drugs continues to plague the healthcare industry. Here’s why.
Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.
CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Early detection of breast cancer continues to be the best way to save lives and decrease healthcare costs over time, and new technology could help.
Managing the care for members with cancer is unlike managing care for other chronic diseases. Here’s five ways to better care for cancer patients.